MDR1 Gene Expression: Evaluation of its Use as a Molecular Marker for Prognosis and Chemotherapy of Bone and Soft Tissue Sarcomas

European Journal of Cancer

Volumn 32, Issue 1, 1996, Pages 86-92

  Stein, U ^a   Shoemaker, R H ^b   Schlag, P M ^c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Section of Pathology   (Germany)

Author keywords

Bone and soft tissue sarcomas; MDR1 gene; Multidrug resistance; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P;

ARTICLE; CANCER CHEMOTHERAPY; GENE EXPRESSION; HUMAN; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE SARCOMA;

BONE NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; P-GLYCOPROTEIN; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029866981     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00478-5     Document Type: Article

References (82)

1. Campanacci M. Bone and Soft Tissue Tumors. Wien, Springer Verlag, 1990.
2. Schlag PM, Winkler K. Weichteilsarkome. Diagnostik und Therapie. Stuttgart, Springer Verlag, 1992.
3. Souhami RL. Chemotherapy of osteosarcomas. Br J Cancer 1989, 59, 147-148.
4. Bramwell VHC. Chemotherapy for metastatic soft tissue sarcomas -another full circle? Br J Cancer 1991, 64, 7-9.
5. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese Hamster cells in vitro. Cross-resistance, radioautographic and cytogenetic studies. Cancer Res 1970, 30, 1174-1184.
6. Roninson IB. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York, Plenum Press, 1991.
7. Germann UA, Pastan I, Gottesman MM. P-glycoproteins: mediators of multidrug resistance. Semin Cell Biol 1993, 4, 63-76.
8. Ling V. P-glycoprotein and resistance to anticancer drugs. Cancer 1992, 69, 2603-2609.
9. Roninson IB. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 1992, 43, 95-102.
10. Chin K-V, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993, 60, 157-180.
11. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissue. Proc Natl Acad Sci USA 1987, 84, 7735-7738.
12. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990, 38, 1277-1287.
13. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84,265-269.
14. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 81, 116-124.
15. Nooter K. Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br J Cancer 1991, 63, 663-669.
16. Gerlach JH, Bell DR, Karakousis C. P-glycoprotein in human sarcomas. J Clin Oncol 1987, 5, 1452-1460.
17. Chan HSL, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcomas of childhood. J Clin Oncol 1990, 8, 689-704.
18. Noonan KF, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990, 87, 7160-7164.
19. Tawa A, Inoue M, Ishihara S. Increased expression of the multidrug-resistance gene in undifferentiated sarcoma. Cancer 1990, 66, 1980-1983.
20. Axiotis C, Hijazi Y, Jefferson J, Tsokos M. Expression of P-glycoprotein in small round cell tumors of childhood. Lab Invest 1991, 64, IP.
21. Hijazi Y, Tsokos M, Navarro S, Horowitz M, Axiotis C. Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral neuroectodermal tumors (PNET) before and after chemotherapy. Lab Invest 1991, 64, 5A.
22. Leuschner I, Schmidt D, Hoffman H, Dietel M, Harms D. Expression of P-glycoprotein in soft tissue tumors of childhood. Correlation of treatment response. J Cancer Res Clin Oncol 1991, 117 (III), 97.
23. Toffoli G, Frustaci S, Tumiotto L, et al. Expression of MDR1 and GST-p in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Ann Oncol 1992, 3, 63-69.
24. Stein U, Wunderlich V, Haensch W, Schmidt-Peter P. Expression of the MDR1 gene in bone and soft tissue sarcomas of adult patients. Eur J Cancer 1993, 29A, 1979-1981.
25. Vergier B, Cany L, Bonnet F, Rober J, De Mascarel A, Coindre JM. Expression of MDR1/P-glycoprotein in human sarcomas. Br J Cancer 1993, 68, 1221-1226.
26. Roessner A, Ueda Y, Bockhorn-Dworniczak B, et al. Prognostic implication of immunodetection of P-glycoprotein in Ewing's sarcoma. J Cancer Res Clin Oncol 1993, 119, 185-189.
27. Chan HSL, Thorner PS, Haddad G, DeBoer G, Ling V. Multidrug resistance in sarcomas of children. In Novak JF, McMaster JH, eds. Frontiers of Osteosarcoma Research. Hogrefe & Huber Publishers, 1993, 51-63.
28. Wunder JS, Bell RS, Wold L, Andrulis IL. Expression of the multidrug resistance gene and clinical outcome in osteosarcomas. In Novak JF, McMaster JH, eds. Frontiers of Osteosarcoma Research. Hogrefe & Huber Publishers, 1993, 71-74.
29. Bodey B, Psenko V, Young L, et al. Immunocytochemical detection of the multidrug resistance (MDR) protein, p170 overexpression in human osteosarcoma (OS) cells. Proc Am Assoc Cancer Res 1994, 35, 471.
30. Leonardo E, Valente G, Cappia S, et al. Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57. Int J Cancer 1994, 57, 841-846.
31. Mauer HM, Beltangady M, Gehan EA, et al. The intergroup rhabdomyosarcoma study-I. Cancer 1988, 61, 209-220.
32. Beahrs OH, Henson DE, Hutter RVP, MyersMH. Musculoskeletal sites. In Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for Staging Cancer. Philadelphia, JB Lippincott Company, 3rd ed., 1988, 123-125.
33. Enzinger FM, Weiss SW. Soft Tissue Tumours. St Louis, Mosby, 1983.
34. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980, 153, 106-120.
35. Kohno K, Sato S-I, Takano H, Matsuo K-I, Kuwano M. The direct activation of human multidrug resistance gene (mdr1) by anticancer agents. Biochem Biophys Res Commun 1989, 165, 1415-1421.
36. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993, 81, 2215-2222.
37. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Monoclonal antibodies detecting P-glycoprotein in multidrug resistant cell lines. Nature 1985, 316, 820-823.
38. Scheper RJ, Bulte JWM, Brakkee JP, et al. Monoclonal antibody JSB-I detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int J Cancer 1988, 42, 389-394.
39. Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994, 54, 1536-1541.
40. Hamada H, Tsuruo T. Functional role for the 170- and 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986, 83, 7785-7789.
41. Schinkel AH, Roelofs MEM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991, 51, 2628-2635.
42. Gottesman MM, Goldstein LJ, Bruggemann E, et al. Molecular diagnosis of multidrug resistance. Cancer Cells 1989, 7, 75-80.
43. Wu L, Smythe AM, Stinson SF, et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 1992, 52, 3029-3034.
44. Schlaifer D, Laurent G, Chittal S, et al. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. Br J Cancer 1990, 62, 177-182.
45. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. BrJ Cancer 1994, 69, 979-985.
46. Uchiumi T, Kohno K, Tanimura H, Hidaka K, Asakuno K, Abe H. Involvement of protein kinase in environmental stress-induced activation of human multidrug resistance 1 (MDR1) gene promoter. FEBS Lett 1993, 326, 11-16.
47. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993, 85, 632-639.
48. Stein U, Walther W, Wunderlich V. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to MDR relevant drugs. Eur J Cancer 1994, 30A, 1541-1545.
49. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1990, 83, 154-155.
50. Levine MN, Browman GP, Gent M, Roberts R, Goodyear M. When is a prognostic factor useful?: A guide for the perplexed. J Clin Oncol 1991, 9, 348-356.
51. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993, 85, 1206-1219.
52. Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. CancerMetastRev 1994, 13, 223-233.
53. Charpin C, Vielh P, Duffaud F, et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994, 86, 1539-1545.
54. Holmes JA, West RR. The effect of MDR-1 gene expression on outcome in acute myeloblastic leukemia. Br J Cancer 1994, 69, 382-384.
55. Rischin D, Ling V. Multidrug resistance in leukemia. In Freireich EJ, Kantarjian H, eds. Leukemia: Advances Research and Treatment. Dordrecht, Boston, Kluwer Academic Publishers, London, 1993, 269-293.
56. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989, 7, 415-424.
57. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991, 325, 1608-1614.
58. Chan HSL, Thorner PS, Haddad G, Gallie B. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology 1991, 98, 1425-1431.
59. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993, 11, 1629-1635.
60. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993, 11, 1652-1660.
61. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993, 72, 3553-3563.
62. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 1993, 72, 3502-3514.
63. Sonneveld P, Schoester M, de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994, 12, 1584-1591.
64. Halloran PF, Madrenas J. The mechanism of action of cyclosporine: a perspective for the 90s. Clin Biochem 1991, 24, 3-7.
65. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporine A and FK506. J Biol Chem 1993, 268, 6077-6080.
66. Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991, 51, 2720-2726.
67. Hennequin E, Delvincourt C, Pourny C, Jardillier JC. Expression of the MDR1 gene in human breast primary tumors and metastases. Breast Cancer Res Treat 1993, 26, 267-274.
68. Mattern J, Volm M. Multiple pathway drug resistance (Review). Int J Oncol 1993, 2, 557-561.
69. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug resistant human breast cancer cells. J Biol Chem 1986, 261, 15544-15549.
70. Kantor RRS, Giardina SL, Bartolazzi A, et al. Monoclonal antibodies to glutathione S-transferase pi-immunohistochemical analysis of human tissues and cancer. Int J Cancer 1991, 47, 193-201.
71. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54, 4313-4320.
72. Danks MK, Schmidt CA, Cirtain MC, Shuttle DP, Beck WT. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 1988, 27, 8861-8869.
73. Gudkov AV, Zelnick CR, Kazarov AR, et al. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 1993, 90, 3231-3235.
74. Schneider E, Horton JK, Yang C-H, Kakagawa M, Cowan KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 1994, 54, 152-158.
75. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1652.
76. Zaman GJR, Versantvoort CHM, Smit JJM, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993, 53, 1747-1750.
77. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994, 54, 357-361.
78. Zaman GJR, Flens MJ, van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc NatlAcad Sci USA 1994, 91, 8822-8826.
79. Flens MJ, Izquierdo MA, Scheffer GL, et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994, 54, 4557-4563.
80. Versantvoort CH, Twentyman PR, Barrand MA, Lankelma J, Pinedo HM, Broxterman JH. Overexpression of 110 and 190 kD proteins in cancer cells may be involved in drug resistant phenotype. Proc Am Assoc Cancer Res 1992, 33, 456.
81. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993, 53, 1475-1479.
82. Gottesman MM. Molecular basis of cancer therapy. J Natl Cancer Inst 1994, 86, 1277-1285.